CareLit · DOI-Nachweis · Geburtshilfe und Frauenheilkunde
Which tyrosinekinase inhibitor for which patient? – VEGFR, target therapy
DOI 10.1055/s-0028-1089303
Bibliografische Angaben
Nachweis in CareLit
Autor:innenC Schem, M Kummerfeld, DO Bauerschlag, C Mundhenke, B Sipos, N Maass
ZeitschriftGeburtshilfe und Frauenheilkunde
Ausgabe09/2008
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
Since the specific HER2 antibody trastuzumab is available, targeted therapy for breast cancer patients is becoming more and more the focus of new drug development. Additional tyrosine kinase inhibitors or antibodies are flooding the market for breast cancer treatment. Currently there are no indices available pointing out which patient will benefit best from these drugs. In this study we analyzed 156 paraffin embedde…
Zitieren
Zitierempfehlung
C Schem, M Kummerfeld, DO Bauerschlag, C Mundhenke, B Sipos, N Maass (2008) Which tyrosinekinase inhibitor for which patient? – VEGFR, target therapy. Geburtshilfe und Frauenheilkunde (09). https://doi.org/10.1055/s-0028-1089303
Mit CareLit weiterarbeiten